30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Iovance Biotherapeutics Inc (IOVA)

Track

The most recent insider trading activity occurred on June 5, 2025, with a BUY transaction by the Chief Commercial Officer. Prior to this, several BUY transactions were made by executives in May 2025. The most significant recent BUY activity was in February 2024, involving substantial share purchases by key executives. A notable SELL transaction occurred in November 2024.
Stock chart
Ticker: IOVA Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Kirby Daniel Gordon
Chief Commercial Officer
1 purchase — total 55,200 USD
Buy 5 Jun 2025
Value US$4,230,550.44 | Price 152.58 | Shares 65,854
Buy 23 May 2025
Value US$3,411,751.75 | Price 250.11 | Shares 66,236
Buy 14 May 2025
Value US$42,250.00 | Price 1.69 | Shares 25,000
Sale 12 Nov 2024
Value US$503,000.00 | Price 10.06 | Shares 50,000
Proposed sale 12 Nov 2024
Value US$503,103.83 | Price 10.06 | Shares 50,000
Buy 20 Feb 2024
Value US$2,287,500.00 | Price 9.15 | Shares 250,000
Buy 20 Feb 2024
Value US$45,750,000.00 | Price 9.15 | Shares 5,000,000
Buy 20 Feb 2024
Value US$292,800.00 | Price 9.15 | Shares 32,000
Buy 18 Sep 2023
Value US$55,600.00 | Price 5.56 | Shares 10,000
Buy 15 Sep 2023
Value US$26,500,000.00 | Price 5.30 | Shares 5,000,000
Buy 21 Dec 2022
Value US$61,500.00 | Price 6.15 | Shares 10,000
Buy 2 Dec 2022
Value US$65,000,000.00 | Price 6.50 | Shares 10,000,000
Buy 29 Nov 2022
Value US$63,100.00 | Price 6.31 | Shares 10,000
Buy 28 Nov 2022
Value US$61,800.00 | Price 6.18 | Shares 10,000
Buy 28 Nov 2022
Value US$5,980.00 | Price 5.98 | Shares 1,000
Buy 23 Nov 2022
Value US$61,000.00 | Price 6.10 | Shares 10,000
Buy 1 Jun 2022
Value US$3,215,500.00 | Price 6.43 | Shares 500,000
Buy 1 Jun 2022
Value US$6,440.00 | Price 6.44 | Shares 1,000
Buy 31 May 2022
Value US$68,000.00 | Price 6.80 | Shares 10,000
Buy 31 May 2022
Value US$68,400.00 | Price 6.84 | Shares 10,000
Buy 31 May 2022
Value US$3,384,550.00 | Price 6.77 | Shares 500,000
Buy 31 May 2022
Value US$53,128.40 | Price 6.80 | Shares 7,813
Buy 31 May 2022
Value US$14,849.73 | Price 6.79 | Shares 2,187
Buy 31 May 2022
Value US$50,587.50 | Price 6.75 | Shares 7,500
Buy 18 Dec 2018
Value US$103,796.40 | Price 8.65 | Shares 12,000
Buy 13 Dec 2018
Value US$96,273.00 | Price 9.63 | Shares 10,000
Buy 6 Dec 2018
Value US$2,958,000.00 | Price 9.86 | Shares 300,000
Buy 4 Dec 2018
Value US$9,496,056.43 | Price 10.31 | Shares 921,053
Sale 22 Aug 2016
Value US$491,740.20 | Price 9.11 | Shares 54,000
Sale 8 Sep 2015
Value US$117,645.00 | Price 7.13 | Shares 16,500
Sale 4 Sep 2015
Value US$109,440.00 | Price 6.84 | Shares 16,000
Sale 3 Aug 2015
Value US$264,875.00 | Price 8.15 | Shares 32,500
Sale 6 May 2015
Value US$500,000.00 | Price 10.00 | Shares 50,000
Sale 1 May 2015
Value US$26,752,385.39 | Price 9.62 | Shares 2,780,682
Sale 6 Nov 2014
Value US$69,000,000,000.00 | Price 690,000.00 | Shares 100,000
Buy 5 Nov 2013
Value US$100,000.00 | Price 2.00 | Shares 50,000
Buy 5 Nov 2013
Value US$250,000.00 | Price 2.00 | Shares 125,000
Buy 21 Jul 2011
Value US$14,000.00 | Price 1.40 | Shares 10,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-06-06 2025-06-05 B Purchase
2.3
Kirby Daniel Gordon

Chief Commercial Officer

Officer
65,854 +42.9%
152.58
US$4,230,550 		65,854 +42.9% 152.58 US$4,230,550
2025-05-27 2025-05-23 B Purchase
3.1
Puri Raj K.

Chief Regulatory Officer

Officer
66,236 +1.3%
250.11
US$3,411,752 		66,236 +1.3% 250.11 US$3,411,752
2025-05-16 2025-05-14 B Purchase
4.0
Vogt Frederick G

Interim CEO & General Counsel

Executive Director
15,007 +26.4%
10.63
US$4,039,378 		15,007 +26.4% 10.63 US$4,039,378
2024-11-14 2024-11-12 S Sale
3.3
Maynard Ryan D
Non-Executive Director
50,000 -87.0%
10.06
US$503,000 		50,000 -87.0% 10.06 US$503,000
2024-11-12 2024-11-12 PrS Proposed sale
3.3
Maynard Ryan D

Director

Non-Executive Director
50,000
10.06
US$503,104 		50,000 10.06 US$503,104
2024-02-20 2024-02-20 B Purchase
3.8
MCPEAK MERRILL A
Non-Executive Director
250,000 +356.4%
9.15
US$2,287,500 		250,000 +356.4% 9.15 US$2,287,500
2024-02-20 2024-02-20 B Purchase
2.9
Rothbaum Wayne P.
Non-Executive Director
5,000,000 +21.7%
9.15
US$45,750,000 		5,000,000 +21.7% 9.15 US$45,750,000
2024-02-20 2024-02-20 B Purchase
2.2
Dukes Iain D.
Non-Executive Director
32,000 +145.5%
9.15
US$292,800 		32,000 +145.5% 9.15 US$292,800
2023-09-19 2023-09-18 B Purchase
3.8
MCPEAK MERRILL A
Non-Executive Director
10,000 +4.2%
5.56
US$55,600 		10,000 +4.2% 5.56 US$55,600
2023-09-15 2023-09-15 B Purchase
2.9
Rothbaum Wayne P.
Non-Executive Director
5,000,000 +27.7%
5.30
US$26,500,000 		5,000,000 +27.7% 5.30 US$26,500,000
2022-12-22 2022-12-21 B Purchase
3.8
MCPEAK MERRILL A
Non-Executive Director
10,000 +16.6%
6.15
US$61,500 		10,000 +16.6% 6.15 US$61,500
2022-12-02 2022-12-02 B Purchase
2.9
Rothbaum Wayne P.
Non-Executive Director
10,000,000 +124.0%
6.50
US$65,000,000 		10,000,000 +124.0% 6.50 US$65,000,000
2022-11-30 2022-11-29 B Purchase
3.8
MCPEAK MERRILL A
Non-Executive Director
10,000 +4.4%
6.31
US$63,100 		10,000 +4.4% 6.31 US$63,100
2022-11-28 2022-11-28 B Purchase
3.8
MCPEAK MERRILL A
Non-Executive Director
10,000 +4.6%
6.18
US$61,800 		10,000 +4.6% 6.18 US$61,800
2022-11-28 2022-11-28 B Purchase
4.0
Vogt Frederick G

Interim CEO & General Counsel

Officer
1,000 +100.0%
5.98
US$5,980 		1,000 +100.0% 5.98 US$5,980
2022-11-28 2022-11-23 B Purchase
2.2
Dukes Iain D.
Non-Executive Director
10,000 +83.3%
6.10
US$61,000 		10,000 +83.3% 6.10 US$61,000
2022-06-02 2022-06-01 B Purchase
2.9
Rothbaum Wayne P.
Non-Executive Director
500,000 +6.6%
6.43
US$3,215,500 		500,000 +6.6% 6.43 US$3,215,500
2022-06-02 2022-06-01 B Purchase
4.0
Vogt Frederick G

Interim CEO & General Counsel

Officer
1,000 +inf%
6.44
US$6,440 		1,000 +inf% 6.44 US$6,440
2022-06-02 2022-05-31 B Purchase
3.8
MCPEAK MERRILL A
Non-Executive Director
10,000 +4.8%
6.80
US$68,000 		10,000 +4.8% 6.80 US$68,000
2022-06-02 2022-05-31 B Purchase
3.8
MCPEAK MERRILL A
Non-Executive Director
10,000 +98.5%
6.84
US$68,400 		10,000 +98.5% 6.84 US$68,400
2022-06-02 2022-05-31 B Purchase
2.9
Rothbaum Wayne P.
Non-Executive Director
500,000 +7.1%
6.77
US$3,384,550 		500,000 +7.1% 6.77 US$3,384,550
2022-06-02 2022-05-31 B Purchase
3.3
WEISER MICHAEL
Non-Executive Director
7,813 +7.5%
6.80
US$53,128 		7,813 +7.5% 6.80 US$53,128
2022-06-02 2022-05-31 B Purchase
3.3
WEISER MICHAEL
Non-Executive Director
2,187 +2.1%
6.79
US$14,850 		2,187 +2.1% 6.79 US$14,850
2022-06-02 2022-05-31 B Purchase
3.3
Maynard Ryan D
Non-Executive Director
7,500 +inf%
6.75
US$50,588 		7,500 +inf% 6.75 US$50,588
2018-12-20 2018-12-18 B Purchase Dukes Iain D. Non-Executive Director
12,000 +inf%
8.65
US$103,796 		12,000 +inf% 8.65 US$103,796
2018-12-14 2018-12-13 B Purchase MCPEAK MERRILL A Non-Executive Director
10,000 +2.2%
9.63
US$96,273 		10,000 +2.2% 9.63 US$96,273
2018-12-07 2018-12-06 B Purchase Rothbaum Wayne P. Non-Executive Director
300,000 +4.4%
9.86
US$2,958,000 		300,000 +4.4% 9.86 US$2,958,000
2018-12-07 2018-12-04 B Purchase Rothbaum Wayne P. Non-Executive Director
921,053 +15.8%
10.31
US$9,496,056 		921,053 +15.8% 10.31 US$9,496,056
2016-08-24 2016-08-22 S Sale Hillsberg Sanford Non-Executive Director
54,000 -35.1%
9.11
US$491,740 		54,000 -35.1% 9.11 US$491,740
2015-09-09 2015-09-08 S Sale Hillsberg Sanford Non-Executive Director
16,500 -9.7%
7.13
US$117,645 		16,500 -9.7% 7.13 US$117,645
2015-09-09 2015-09-04 S Sale Hillsberg Sanford Non-Executive Director
16,000 -8.6%
6.84
US$109,440 		16,000 -8.6% 6.84 US$109,440
2015-08-04 2015-08-03 S Sale Hillsberg Sanford Non-Executive Director
32,500 -14.8%
8.15
US$264,875 		32,500 -14.8% 8.15 US$264,875
2015-05-07 2015-05-06 S Sale Hillsberg Sanford Non-Executive Director
50,000 -18.6%
10.00
US$500,000 		50,000 -18.6% 10.00 US$500,000
2015-05-08 2015-05-01 S Sale Ayer Capital Management, LP Large shareholder
2,780,682 -49.6%
9.62
US$26,752,385 		2,780,682 -49.6% 9.62 US$26,752,385
2014-11-07 2014-11-06 S Sale BRISTOL INVESTMENT FUND LTD Large shareholder
100,000 -2.5%
690,000.00
US$69,000,000,000 		100,000 -2.5% 690,000.00 US$69,000,000,000
2013-11-12 2013-11-05 B Purchase MCPEAK MERRILL A/ Non-Executive Director
50,000 +14.4%
2.00
US$100,000 		50,000 +14.4% 2.00 US$100,000
2013-11-07 2013-11-05 B Purchase Singh Manish

President & CEO

Executive Director Large shareholder
125,000 +6.9%
2.00
US$250,000 		125,000 +6.9% 2.00 US$250,000
2011-09-26 2011-07-21 B Purchase MCPEAK MERRILL A/ Non-Executive Director
10,000 +inf%
1.40
US$14,000 		10,000 +inf% 1.40 US$14,000
Explore more

More insider trading research around Iovance Biotherapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America